Clinical Trial Detail

NCT ID NCT03402841
Title Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

ovarian serous carcinoma

endometrioid ovary carcinoma

peritoneum cancer

fallopian tube cancer

Therapies

Olaparib

Age Groups: adult senior

No variant requirements are available.